Based on this study, in 2014 the Canadian Cardiovascular Society (CCS) (29) updated its guidelines for the management of patients with heart failure, recommending for the first time a dual angiotensin receptor and enkephalinase inhibitor (ARNI). This evidence concerns the gene MME and heart failure.